17 March 2006

FUNDING AND CORPORATE FOCUS ON THROMBOVIEW

Agenix reconfirmed today that its primary focus is to negotiate a partnering deal for its lead product, ThromboView®, in an expeditious timeframe and which seeks to maximise value for all shareholders in the company. Concurrently, the company is implementing a focused strategy of developing a broad pipeline of monoclonal antibody based products by leveraging the company's core expertise in monoclonal antibody development and demonstrated capability to take target compounds from the bench through Phase II clinical studies.

Agenix is one of the few companies in Australia with significant expertise in the development of biologics, a rapidly growing sector with an increasing number of antibodies in preclinical and clinical development.

Agenix CEO and Managing Director, Mr Neil Leggett, stated "The greatest value driver in achieving a partnering deal which has mutual advantage for both parties will come from the completion of a comprehensive data package to support the acceleration of ThromboView® towards later phase trials in PE (pulmonary embolism or blood clot in the lung)."

"Our focus is on securing the best deal to maximise shareholder value based on exciting trial results in PE. Partnership discussions remain active with a number of potential partners; each at different stages of negotiation and approaching the opportunity from different perspectives".

"PE is the primary indication of interest to potential partners. Independent analysis of results from our recent ThromboView® Phase Ib PE trial confirmed a high sensitivity of ThromboView® for detection of PE. Diagnosis of PE remains a medical challenge due to limitations of existing techniques in a variety of common patient settings."

With the focus on the development of a strong partnering data package for ThromboView®, the Agenix Board has determined to evaluate the disposal of its non-core human health and animal health diagnostic test businesses.

Funds from the prospective sale of these businesses and a private placement announced today will be applied towards achieving a commercial outcome for ThromboView® and implementation of key initiatives towards developing a broad pipeline of monoclonal antibody based products.

The placement has raised $3.0 million before costs from the placement of 13.6 million shares at $0.22. The shares were placed with institutions and sophisticated investors introduced by Intersuisse Limited.

END

For more information, please contact:

Mr Neil Leggett
CEO and Managing Director
Agenix Limited
Ph: 61 7 3370 6300

Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY] is a global health and biotechnology company based in Brisbane, Australia. The Company runs a suite of profitable and established businesses in human and animal health diagnostics and is focused on growing its world-leading molecular diagnostic imaging R&D program.

Agenix's lead candidate is its high-technology ThromboView® blood clot-imaging project, which is currently undergoing human trials. ThromboView® uses radiolabelled antibodies to locate blood clots in the body, and could revolutionise the US $3 billion global clot diagnostic imaging market. ThromboView® is being developed with the assistance of the Federal Government through its START scheme.

Agenix employs 90 staff and sells its products to more than 50 countries. ThromboView® is a registered trademark of AGEN Biomedical Ltd, a wholly owned subsidiary of Agenix Limited.

www.agenix.com